PT  - JOURNAL ARTICLE
AU  - Camille Roubille
AU  - Nathalie Rincheval
AU  - Maxime Dougados
AU  - René-Marc Flipo
AU  - Jean-Pierre Daurès
AU  - Bernard Combe
TI  - Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort
AID  - 10.1136/annrheumdis-2016-210135
DP  - 2017 Nov 01
TA  - Annals of the Rheumatic Diseases
PG  - 1797--1802
VI  - 76
IP  - 11
4099  - http://ard.bmj.com/content/76/11/1797.short
4100  - http://ard.bmj.com/content/76/11/1797.full
SO  - Ann Rheum Dis2017 Nov 01; 76
AB  - Objective To explore the 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA).Methods We examined data for 602 patients with RA from the early arthritis Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort (<6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years (IQR 0.038–7.65)). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture.Results Among the 602 patients with RA (476 women (79%), mean age 48±12 years), 386 with GC (64.1%) received low-dose prednisone (mean 3.1±2.9 mg/day for the entire follow-up): 263 started GC during the first 6 months (68%), and the mean duration of total GC treatment was 1057±876 days. As compared with patients without GC (216 (35.9%)), those with GC showed greater use of non-steroidal anti-inflammatory drugs, synthetic and biological disease-modifying antirheumatic drugs and had more active disease disability, higher C reactive protein and anticitrullinated protein antibody levels. Among 65 events (7 deaths, 14 cardiovascular diseases, 19 severe infections and 25 fractures), 44 and 21 occurred in patients with and without GC (p=0.520). Infections were more frequent, although not significantly, in patients with than without GC (p=0.09). On weighted Cox proportional-hazards analysis, with use of propensity score and inverse-probability-of-treatment weighting, and including age, gender, history of hypertension and GC treatment, outcomes did not differ with and without GC (p=0.520; HR=0.889; 95% CI 0.620 to 1.273).Conclusions This 7-year analysis of the ESPOIR cohort supports the good safety profile of very low-dose GC for early active RA.